LFVN vs. RZLT, FBLG, ACIU, CTNM, ANL, VTYX, VRCA, ORGO, STTK, and SKYE
Should you be buying LifeVantage stock or one of its competitors? The main competitors of LifeVantage include Rezolute (RZLT), FibroBiologics (FBLG), AC Immune (ACIU), Contineum Therapeutics (CTNM), Adlai Nortye (ANL), Ventyx Biosciences (VTYX), Verrica Pharmaceuticals (VRCA), Organogenesis (ORGO), Shattuck Labs (STTK), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical preparations" industry.
Rezolute (NASDAQ:RZLT) and LifeVantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.
LifeVantage received 165 more outperform votes than Rezolute when rated by MarketBeat users. Likewise, 77.82% of users gave LifeVantage an outperform vote while only 75.68% of users gave Rezolute an outperform vote.
Rezolute has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, LifeVantage has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.
83.0% of Rezolute shares are owned by institutional investors. Comparatively, 35.3% of LifeVantage shares are owned by institutional investors. 20.8% of Rezolute shares are owned by company insiders. Comparatively, 6.8% of LifeVantage shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
LifeVantage has a net margin of 1.75% compared to LifeVantage's net margin of 0.00%. Rezolute's return on equity of 27.02% beat LifeVantage's return on equity.
LifeVantage has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks.
Rezolute currently has a consensus price target of $8.80, suggesting a potential upside of 112.05%. Given LifeVantage's higher possible upside, research analysts plainly believe Rezolute is more favorable than LifeVantage.
In the previous week, Rezolute had 3 more articles in the media than LifeVantage. MarketBeat recorded 8 mentions for Rezolute and 5 mentions for LifeVantage. LifeVantage's average media sentiment score of 1.13 beat Rezolute's score of 0.91 indicating that Rezolute is being referred to more favorably in the media.
Summary
LifeVantage beats Rezolute on 9 of the 16 factors compared between the two stocks.
Get LifeVantage News Delivered to You Automatically
Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LFVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LifeVantage Competitors List
Related Companies and Tools
